Identifies TRIM21 as a regulator of STAT1 in metabolic dysfunction, suggesting new therapeutic avenues for steatohepatitis.
The ubiquitination of STAT1 in MASH is regulated by TRIM21 which is a key suppressor of MASH. TRIM21 acts as a negative regulator in hepatic steatosis and offers potential therapeutic opportunities for MASH.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: